• Office for Cancer Registry, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China;
SUN Kexin, Email: skxgentle@cicams.ac.cn; ZHENG Rongshou, Email: zhengrongshou@163.com
Export PDF Favorites Scan Get Citation

Objective To provide a basis for timely adjustment of cancer prevention and control measures in China through timely understanding of the latest 2022 global cancer statistics reported in the CA: A Cancer Journal for Clinicians published “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. Methods The statistical data of GLOBOCAN in 2022 were systematically analyzed and the incidence and mortality of cancer by age, sex, type, and region were comprehensively interpreted. The changing trends in cancer were compared between China and the rest of the world, and the potential risk factors as well as current cancer prevention and control measures were summarized. Results ① Globally, for both sexes combined, there were an estimated 19.976 million new cases and 9.744 million cancer deaths in 2022. The age-standardized incidence rate (ASIR) was 196.9 per 100 000 and the age-standardized mortality rate (ASMR) was 91.7 per 100 000 in 2022. The ASIR of all cancers was highest in Europe (268.1 per 100 000) and lowest in South-East Asia (109.6 per 100 000), as well as the ASMR of all cancers was highest in Europe (106.3 per 100 000) and lowest in South-East Asia (71.0 per 100 000). The top three cancer types of newly diagnosed cancer cases were lung, breast, and colorectal cancer, while the top three leading causes of cancer deaths were lung, colorectal, and liver cancer. The incidence and mortality rates of all cancers increased with advancing age. The numbers of newly diagnosed cancer cases and cancer deaths, as well as the age-standardized rates were consistently higher among men compared to women. The lung cancer and breast cancer ranked first in terms of newly diagnosed cancer cases among men and women, respectively. Consistently, the lung cancer and breast cancer were also the leading causes of cancer-related deaths among men and women, respectively. ② In China, there were an estimated 4.825 million new cases and 2.574 million cancer deaths. The ASIR was 201.6 per 100 000 and the ASMR was 96.5 per 100 000 in 2022. The ASIR and ASMR both ranked 65th out of 185 countries. The top three cancer types among newly diagnosed cases were lung cancer, colorectal cancer, and thyroid cancer, while the top three leading causes of cancer deaths were lung cancer, liver cancer, and gastric cancer. Conclusions The cancers incidences and deaths worldwide in 2022 have declined from that in 2020 (196.9 per 100 000 versus 201.0 per 100 000, 91.7 per 100 000 versus 100.7 per 100 000, respectively). Lung cancer is the leading type of newly diagnosed cancer both in China and globally. However, the second and third most common cancers in China differ from the global picture. In China, colorectal cancer and thyroid cancer take the second and third spots, respectively; Whereas globally, breast cancer and colorectal cancer occupy these positions. Lung cancer is the first ranked leading cause of death in both China and globally. However, there are differences in the second and third most common causes. In China, liver cancer and gastic cancer take the second and third spots, respectively; While globally, colorectal cancer and liver cancer occupy these positions. This study analyzes the characteristics of the disease burden of cancer in China by comparing the epidemiological features of cancer in China and worldwide, aiming to provide scientific evidences for developing comprehensive cancer prevention and control measures tailored specifically to China’s national conditions.

Citation: YAO Yifei, SUN Kexin, ZHENG Rongshou. Interpretation and analysis of the Global Cancer Statistics Report 2022:a comparison between China and the world. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(7): 769-780. doi: 10.7507/1007-9424.202406046 Copy

  • Previous Article

    Treatment of COVID-19 during esophageal cancer surgery: A case report
  • Next Article

    Epidemiological characteristics of liver cancer worldwide and in China: an interpretation of global cancer statistics 2022